Researcher index

Authors in the psilocybin and psilocin literature

Search researcher names, inspect publication history, find recurring topics, and create author watch alerts without collecting unverified contact lists.

Bhuiya NMA

30 indexed publications match this author name.

ORCID: Not found in stored metadata
OpenAlex: Not found in stored metadata

Author watchlist

Create a confirmed email alert for new publications matching this author.

Topics

Receptor Pharmacology 16 Depression 10 Brain Imaging 10 Safety 8 Emotional Processing 8 Anxiety 7 Aging 6 Healthy Volunteers 6 Chronic Pain 5 Clinical Trial 4 Mechanism of Action 4 Review Article 4

Journals

ClinicalTrials.gov 7 European Neuropsychopharmacology 3 Scientific reports 2 European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology 2 Cureus 1 Research Square 1 Preprints.org 1 Frontiers in psychiatry 1

Publication history

A Phase III, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With Treatment-resistant DepressionClinicalTrials.gov · 2026-08-10 The Safety and Efficacy of Psilocybin Therapy Compared to Low-dose Control in Reducing Depressive Symptoms in Patients With COPD, ALS, MS, or APD.ClinicalTrials.gov · 2026-05-08 The QUANTUM Trip Trial - Psilocybin-assisted Therapy for Reducing Alcohol Intake in Patients With Alcohol Use Disorder: A Randomized, Double-blinded, Placebo-controlled Clinical Trial.ClinicalTrials.gov · 2026-03-24 The Neurobiological Effect of 5-HT2AR ModulationClinicalTrials.gov · 2024-12-16 Psilocybin for Treatment of Alcohol Use Disorder: a Feasibility StudyClinicalTrials.gov · 2024-07-12 Predictors of Pharmacy Students' Attitudes About the Therapeutic Use of Psilocybin.Cureus · 2023-09-01 Administration effects of four psilocybin mushroom extracts on serotonin levels and endothelial nitric oxide synthase activity levels in vivo and in vitro after one hourResearch Square · 2023-07-18 Cardioprotective Potential of the Ethanol and Water Extracts of Four Psilocybin Mushrooms on Angiotensin II-Induced Hypertrophy and Oxidative Stress on H9C2 CardiomyocytesPreprints.org · 2023-06-06 The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant DepressionClinicalTrials.gov · 2023-04-24 Prophylactic Effects of Psilocybin on Chronic Cluster Headache: an Open-label Clinical Trial and Neuroimaging StudyClinicalTrials.gov · 2022-08-10 Lower-dose psycholytic therapy - A neglected approach.Frontiers in psychiatry · 2022-01-01 Anti-Inflammatory Effects of Four Psilocybin-Containing Magic Mushroom Water Extracts in vitro on 15-Lipoxygenase Activity and on Lipopolysaccharide-Induced Cyclooxygenase-2 and Inflammatory Cytokines in Human U937 Macrophage Cells.DOAJ (DOAJ: Directory of Open Access Journals) · 2021-08-04 Anti-Inflammatory Effects of Four Psilocybin-Containing Magic Mushroom Water Extracts in vitro on 15-Lipoxygenase Activity and on Lipopolysaccharide-Induced Cyclooxygenase-2 and Inflammatory Cytokines in Human U937 Macrophage Cells.Journal of inflammation research · 2021-01-01 Effects and safety of Psilocybe cubensis and Panaeolus cyanescens magic mushroom extracts on endothelin-1-induced hypertrophy and cell injury in cardiomyocytes.Scientific reports · 2020-12-18 Phytochemical, Cytotoxicity, Antioxidant and Anti-Inflammatory Effects of Magic Mushroom.Plants (Basel, Switzerland) · 2020-08-31 Mystical Experiences in Retrospective Reports of First Times Using a Psychedelic in Finland.Journal of psychoactive drugs · 2020-01-01 Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat.Scientific reports · 2019-10-24 Psilocybin modulates functional connectivity of the amygdala during emotional face discrimination.European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology · 2018-06-01 Two dose investigation of the 5-HT-agonist psilocybin on relative and global cerebral blood flow.NeuroImage · 2017-10-01 Dreams and Psychedelics: Neurophenomenological Comparison and Therapeutic Implications.Current neuropharmacology · 2017-01-01 LSD Increases Primary Process Thinking via Serotonin 2A Receptor Activation.Frontiers in pharmacology · 2017-01-01 Psilocybin-induced decrease in amygdala-putamen coupling during an event-related face discrimination taskEuropean Neuropsychopharmacology · 2016-10-01 Effects of serotonin 2A/1A receptor stimulation on social exclusion processing.Proceedings of the National Academy of Sciences of the United States of America · 2016-05-03 Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience.European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology · 2016-04-01 The mixed serotonin receptor agonist psilocybin reduces threat-induced modulation of amygdala connectivity.NeuroImage. Clinical · 2016-01-01 Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers.Biological psychiatry · 2015-10-15 P.1.i.005 The 5-HT2A/1A agonist psilocybin reduces social pain and enhances empathy in healthy volunteersEuropean Neuropsychopharmacology · 2015-09-01 The Effect of 5-HT2A/1a Agonist Treatment On Social Cognition, Empathy, and Social Decision-makingEuropean Psychiatry · 2015-03-01 P.1.g.005 Serotonergic modulation of emotion processing by the mixed 5-HT1A/2A receptor agonist psilocybin reduces amygdala activation to negative stimuli - a pharmacological fMRI studyEuropean Neuropsychopharmacology · 2014-09-25 A Comparison of the Phenomenology of Hallucinogens and Schizophrenia From Some Autobiographical Accounts*Schizophrenia Bulletin · 1976-12-31

Author directory